IQVIA Holdings Inc. - IQV STOCK NEWS

IQVIA (NYSE:IQV) has launched One Home for Sites™, a new technology platform designed to streamline and integrate the various systems and tasks required by clinical research sites. This platform acts as a single sign-on and dashboard, reducing the overload of multiple software applications, thereby freeing up time for site staff to focus on patient recruitment and treatment. One Home for Sites is currently in Beta testing and being piloted by IQVIA Prime Sites, with input from over 100 site personnel. The platform aims to enhance site productivity and accelerate the delivery of new treatments by acting as a neutral aggregator and communicator among various clinical applications.

The IQVIA Institute has released a report detailing the global rise in cancer diagnoses and the corresponding increase in innovative cancer therapies. Cancer incidence is projected to reach 32 million new cases annually by 2050, especially in lower-income countries.

Global spending on cancer medicines rose to $223 billion in 2023 and is expected to hit $409 billion by 2028. The year 2023 saw the launch of 25 novel active substances (NASs) in oncology, bringing the total to 193 since 2014.

Over 2,000 new oncology clinical trials began in 2023, featuring advanced therapies like cell and gene therapies, antibody-drug conjugates, and radioligand therapies. Despite advancements, geographic disparities in access to these therapies persist.

Oncology trials have become less complex, increasing the success rate to 10% in 2023 from 4% the previous year. However, the pace of bringing new therapies to patients remains uneven due to differences in healthcare infrastructure and adoption rates.

Overall spending on medicines in the U.S. grew by 2.5% in 2023, reaching $435 billion. Excluding COVID-19 vaccines and therapeutics, the growth rate was 9.9%, driven by advances in oncology, immunology, diabetes, and obesity treatments. Patient out-of-pocket costs rose to $91 billion, influenced by wider use of GLP-1 agonists for diabetes and obesity. New prescriptions increased by 4%, while patient visits and diagnostics fell by 4-6%. The flu vaccination rate dropped by 17%. The IQVIA Health Services Utilization Index fell 3% to 97. The report projects continued growth in medicine spending, driven by innovation but tempered by patent expirations and the introduction of biosimilars. Net pharmaceutical spending is forecasted to grow at 4-7% annually through 2028, with oncology and obesity as primary growth drivers.

IQVIA Holdings Inc. announced that Ron Bruehlman, CFO, will speak at the Bank of America Health Care Conference on May 14, 2024. The presentation will be webcasted live and available for replay on the IQVIA Investor Relations website.

IQVIA Holdings Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $3,737 million, GAAP Net Income of $288 million, and Adjusted EBITDA of $862 million. The company's First-Quarter 2024 Operating Results showed revenue growth of 2.3% on a reported basis and 2.9% at constant currency. R&D Solutions revenue increased by 3.4%, Technology & Analytics Solutions revenue grew by 0.6%, and Contract Sales & Medical Solutions revenue rose by 3.8%. The company's contracted backlog reached $30.1 billion, up 7.9% year-over-year. IQVIA reaffirmed its full-year guidance for 2024, expecting revenue growth of 2.3% to 3.9% and Adjusted Diluted EPS growth of 7.4% to 10.3% year-over-year.

IQVIA (NYSE:IQV) celebrates Wendy Stewart and Susan Barnes for winning the Healthcare Businesswoman's Association Luminary and Rising Star Awards. Wendy, president of Clinical Operations, led teams in delivering COVID vaccine trials. Susan, senior director of IQVIA Biotech Strategic Operations, drove innovation and mentorship in the business. Both represent IQVIA's values and serve as role models for employees.

IQVIA Holdings Inc. will announce its first-quarter 2024 financial results on May 2, 2024, followed by a conference call and webcast. Investors can access the earnings release and financial information on the IQVIA Investor Relations website.

IQVIA and Salesforce announce an expanded global strategic partnership to accelerate the development of Salesforce's Life Sciences Cloud, combining IQVIA's OCE platform with Salesforce's CRM software to transform healthcare professional and patient engagement. The partnership aims to provide a new end-to-end engagement platform by 2025.

IQVIA Holdings Inc. CFO to speak at Barclays Global Healthcare Conference. Ron Bruehlman, IQVIA's CFO, will present at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024, at 9:30 a.m. ET. The presentation will be live-streamed on the IQVIA Investor Relations website.